Insider Selling: Natera, Inc. (NASDAQ:NTRA) Insider Sells 256 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 256 shares of Natera stock in a transaction on Tuesday, October 22nd. The shares were sold at an average price of $120.07, for a total value of $30,737.92. Following the completion of the transaction, the insider now owns 111,891 shares in the company, valued at approximately $13,434,752.37. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Natera Trading Down 1.1 %

Shares of NASDAQ:NTRA traded down $1.30 during midday trading on Wednesday, reaching $118.65. The company’s stock had a trading volume of 632,741 shares, compared to its average volume of 1,331,355. The firm has a 50 day moving average price of $123.43 and a two-hundred day moving average price of $111.03. Natera, Inc. has a fifty-two week low of $36.90 and a fifty-two week high of $133.54. The firm has a market capitalization of $14.57 billion, a price-to-earnings ratio of -38.03 and a beta of 1.53. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.01 and a current ratio of 4.14.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.39. The firm had revenue of $413.35 million for the quarter, compared to analyst estimates of $343.00 million. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The company’s revenue was up 58.1% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.97) earnings per share. As a group, analysts forecast that Natera, Inc. will post -1.96 earnings per share for the current year.

Institutional Investors Weigh In On Natera

Several hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of Natera by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 11,044,743 shares of the medical research company’s stock worth $1,010,152,000 after acquiring an additional 72,848 shares during the last quarter. Farallon Capital Management LLC grew its holdings in shares of Natera by 13.6% in the second quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company’s stock valued at $483,034,000 after acquiring an additional 532,874 shares in the last quarter. Massachusetts Financial Services Co. MA increased its position in shares of Natera by 6.6% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,397,582 shares of the medical research company’s stock valued at $259,634,000 after purchasing an additional 148,917 shares during the last quarter. Duquesne Family Office LLC increased its holdings in Natera by 2.4% during the second quarter. Duquesne Family Office LLC now owns 1,974,880 shares of the medical research company’s stock worth $213,860,000 after buying an additional 45,500 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC increased its stake in shares of Natera by 25.0% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,229,558 shares of the medical research company’s stock worth $156,092,000 after purchasing an additional 246,246 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on NTRA. BTIG Research boosted their target price on Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Leerink Partners upped their price objective on shares of Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Piper Sandler reissued an “overweight” rating and issued a $150.00 price objective on shares of Natera in a research note on Friday, September 13th. Canaccord Genuity Group upped their price target on shares of Natera from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, August 27th. Finally, TD Cowen boosted their price objective on Natera from $137.00 to $145.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $124.44.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.